Seelaus Asset Management LLC Sells 275 Shares of Hologic, Inc. (NASDAQ:HOLX)

Seelaus Asset Management LLC trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,535 shares of the medical equipment provider’s stock after selling 275 shares during the period. Seelaus Asset Management LLC’s holdings in Hologic were worth $451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Empowered Funds LLC bought a new position in Hologic in the first quarter worth approximately $234,000. Bleakley Financial Group LLC boosted its position in Hologic by 18.3% during the first quarter. Bleakley Financial Group LLC now owns 5,412 shares of the medical equipment provider’s stock valued at $422,000 after purchasing an additional 836 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Hologic by 15.3% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 278,181 shares of the medical equipment provider’s stock valued at $21,687,000 after purchasing an additional 36,898 shares during the last quarter. Banco Santander S.A. bought a new position in Hologic in the first quarter worth about $344,000. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its position in shares of Hologic by 0.4% during the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 292,378 shares of the medical equipment provider’s stock valued at $22,490,000 after buying an additional 1,136 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.4 %

Shares of NASDAQ:HOLX opened at $78.60 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 52-week low of $67.59 and a 52-week high of $84.67. The stock has a market cap of $18.26 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 2.50 and a beta of 0.98. The business has a 50-day moving average price of $80.71 and a 200-day moving average price of $78.23.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the firm posted $0.89 EPS. Equities analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on HOLX shares. UBS Group lifted their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. upped their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada raised their price objective on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Stephens reaffirmed an “overweight” rating and set a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Finally, Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.